RAPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
RAPT Therapeutics is not a good buy for a beginner investor with a long-term strategy at this time. The stock is trading near its acquisition price of $58 per share, leaving minimal upside potential. Analysts have downgraded the stock due to the acquisition, and there are no significant positive catalysts or proprietary trading signals to justify a buy decision.
The stock is overbought with an RSI of 86.067, and the MACD histogram is negatively expanding at -0.629. While moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the price is trading near resistance levels (R1: 57.829, R2: 57.888), indicating limited room for further upside.
The acquisition by GSK at $58 per share provides a clear exit strategy for current shareholders.
The acquisition caps the stock's upside at $58 per share, leaving no room for significant price appreciation. Analysts have downgraded the stock, and hedge funds are heavily selling, with a 392% increase in selling activity last quarter.
In Q3 2025, RAPT reported no revenue growth (0% YoY), a net income drop to -$17.58M (-4.62% YoY), and a significant EPS decline to -0.65 (-82.85% YoY). The company's financials show no signs of improvement.
All analysts have downgraded the stock to neutral or hold ratings following the acquisition announcement. The price target is consistently set at $58, reflecting the acquisition price.
